based on our inclusion and exclusion criteria. The correlation between body mass index and ideal weight gain was analyzed using Pearson test.
Randwick, the 3 Royal Hospital for Women
Background: Following the Parenteral Nutrition consensus, a policy was introduced in a tertiary neonatal intensive care unit to do regular plasma triglycerides and titrate parenteral lipid intakes to maintain plasma triglycerides ?2.8 mmol/L.
Method: A Quality improvement audit was conducted in infants 23-28 weeks gestation admitted to our facility between July 2012 and June 2016. Lipid emulsions were commenced at 1 g/kg/day along with starter Aminoacid/Dextrose immediately after birth and increased by 1 g/kg/day every 24 hours to a maximum of 3 g/kg/day. Plasma triglyceride levels were measured every 24 hours until after reaching 3 g/kg/day and then weekly if remained on lipid emulsion. If triglyceride level is >2.8 mmol/ L, lipid dosage was titrated. Main outcome measures were: (1) compliance to the policy, (2) incidence of hypertriglyceridaemia (HT, plasma triglycerides > 2.8 mmol/L) and (3) association of HT with mortality and major morbidities.
Results: There were 195 eligible infants and the compliance to triglyceride monitoring policy was 89.2%. HT was noted in 19.5% (32.5% in 23-25 wks and 16.1% in 26-28 wks); Nine (4.6%) developed severe HT (>5.5 mmol/L) and 10 (5.1%) had more than 1 episode. HT group was associated with significantly higher mortality (OR 3.49; 95% CI 1.13-10.76) and severe ROP (OR 4.06; 95% CI 1.73-9.59). HT was not an independent risk factor for these outcomes after adjusted for gestation and birthweight percentiles.
Conclusions: HT is common particularly in infants 23-25 week gestation receiving parenteral lipid emulsion. Regular monitoring and titration of lipid intake reduced the adverse influence of HT. Method: We conducted a quality improvement audit to determine the incidence of BUN concentrations <3.2 mmol/L in the first 12 weeks of life among 23-28 weeks gestation infants admitted to our tertiary neonatal facility between July 2012 and June 2016. We routinely administer Aminoacid (AA)/Dextrose and lipid emulsions immediately after birth, providing 2 g/kg/day of intravenous AA on day 1 with gradual increase over the next 5 days to 4 g/kg/day. Enteral protein intake is targeted up to 4.5 g/kg/day using cow's milk based fortifier incrementally added to maternal expressed breast milk (EBM) if tolerated or preterm formulas if inadequate EBM.
TRENDS IN BLOOD UREA NITROGEN AS A MARKER OF PROTEIN INTAKE IN EXTREME PRETERM INFANTS
Results: Among 195 studied infants (mean gestation 26.6 wks; birthweight 970.8 g), the proportion of infants with BUN < 3.2 mmol/L were low in the first 2 weeks of life but increased rapidly to 80% by the 5 th week and remained high during hospital stay.
24 hr Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk9 Wk10 Wk11 Wk12 % inpatients 3% 3% 30% 51% 63% 78% 79% 86% 84% 80% 80% 78% 79%
Feed tolerance was a common limiting factor in protein intake enhancement encountered.
Conclusions: There is a very high incidence of inadequate protein intake in infants 23-28 weeks gestation. A better strategy for improved protein intake needs to be explored. ' and 'Term (corrected) to 28 days' were designed and piloted in 12 Victorian hospitals from August to November 2016. Two types of charts were developed: one for the BirthSuite/Postnatal (BSPN) areas and another for 'Neonates' (up to 28 days) in special care nurseries, emergency departments and paediatric wards. As part of a multimethod evaluation this report examines user satisfaction and determines chart suitability for recording clinical observations and communicating clinical care.
